FrancophonIA/ELRC3.0 huggingface dataset:
English: No notable increase in Cmax and AUC upon multiple dosing (10 mg/kg three times daily) was observed.
Maltese: Ma ġietx ossrvata żjieda notabbli Cmax u l-AUC b'dożaġġ multiplu (10 mg/kg tliet darbiet kuljum).
English: Excretion of ciprofloxacin (% of dose) Oral Administration Urine
Maltese: Tneħħija ta' ciprofloxacin (% tad-doża) Għoti Orali Awrina
English: As it is not compulsory to specify the recommended antibiotic strategy in the wording of the therapeutic indication in the Marketing Authorisation, the CHMP recommended that the proposed 4.1 SPC wording “prophylaxis of invasive infections due to Neisseria meningitidis” remain, and accepted the adult posology: PO: 1 x 500 mg/d (single dose).
Maltese: Minħabba li m'huwiex obbligatorju li listrateġija ta' antibijotiċi rrakkomandata fil-kitba tal-indikazzjoni terapewtika fl-Aworizzazzjoni għatTqegħid fis-Suq tkun speċifikata, is-CHMP irrakkomanda li l-kitba proposta tas-sezzjoni 4.1 tal-SPC “profilassi ta' infezzjonijiet invażivi minħabba Neisseria meningitidis” tibqa', u aċċetta l-pożoloġija tal-adulti: PO: 1 x 500 mg/kuljum (doża waħda).
English: Aerobic Gram-negative micro-organisms
Maltese: Mikro-organiżmi aerobiċi Gram-negative
English: An overdose of 12 g has been reported to lead to mild symptoms of toxicity.
Maltese: Doża eċċessiva ta' 12 g ġiet irrapportata li twassal għall-sintomi ħfief ta' tossiċità.
English: • Gonococcal urethritis and cervicitis (only for oral formulations)
Maltese: • Uretrite u ċerviċite gonokokkali (għall-formulazzjonijiet orali biss)
English: A 60-minute intravenous infusion of 200 mg ciprofloxacin or the oral administration of 250 mg ciprofloxacin, both given every 12 hours, produced an equivalent area under the serum concentration time curve (AUC).
Maltese: Infużjoni fil-vini ta' 60 minuta ta' 200 mg ciprofloxacin jew l-għoti orali ta' 250 mg ciprofloxacin, ittnejn mogħtija kull 12-il siegħa, ipproduċew erja taħt il-kurva (AUC) tal-konċentrazzjoni fis-serum kontra l-ħin ekwivalenti.
English: Clinical trials have included children and adolescents aged 1-17 years.
Maltese: Provi kliniċi inkludew tfal u adoloxxenti b'età ta' 1-17-il sena.
English: Peripheral neuropathy (see section
Maltese: Newropatija periferali (ara sezzjoni
English: When a switch down to oral therapy is possible, a 750 mg bid ciprofloxacin regimen is recommended.
Maltese: Meta bidla għal terapija orali tkun possibbli, huwa rrakkomandat reġimen ta' ciprofloxacin 750 mg bid.
English: Groupings of relevant species according to ciprofloxacin susceptibility (for Streptococcus species see section 4.4)
Maltese: Klassifikazzjoni ta' ispeċi rilevanti skond is-suxxettibilità għal ciprofloxacin (għall-ispeċi ta' Streptococcus ara sezzjoni 4.4)
English: CIPROBAY 5 g/100 ml oral suspension oral use
Maltese: CIPROBAY 5 g/100 ml suspensjoni orali użu orali
English: Taking the suspension
Maltese: Teħid tas-suspensjoni
English: Acute exacerbation of chronic sinusitis
Maltese: Irkadar akut ta' sinusite kronika
English: • Prophylaxis of invasive infections due to Neisseria meningitides (only for oral formulations)
Maltese: • Profilassi ta' infezzjonijiet invażivi minħabba Neisseria meningitides (għall-formulazzjonijiet orali biss)
English: ½ measuring spoonful (approx 2.5-mL suspension) provides approx. 125 mg ciprofloxacin.
Maltese: ½ mgħarfa tal-kejl waħda (madwar 2.5 mL ta' suspensjoni) tipprovdi madwar 125 mg ta' ciprofloxacin
English: The Applicant/MAH provided reports summarizing the results of a literature search from 2001 to 2006, including animal model and clinical articles.
Maltese: L-Applikant/MAH ta rapporti li jagħtu fil-qosor ir-riżultati ta' tfittxija fil-letteratura mill-2001 sal2006, inklużi mudelli tal-annimali u artikoli kliniċi.
English: Serum concentrations increase proportionately with doses up to 1000 mg.
Maltese: Konċentrazzjonijiet fis-serum jiżdiedu b'mod proporzjonali mad-doża b'dożi sa 1000 mg.
English: - exacerbations of chronic obstructive pulmonary disease
Maltese: - irkadar tal-marda pulmonari ostruttiva kronika
English: Prophylaxis of invasive infections of adults due to Neisseria meningitides Ciprofloxacin is used in clinical practice in prophylaxis of invasive infections of adults due to Neisseria meningitidis when rifampicin is contra-indicated or after microbiologically documentation when Neisseria meningitidis is resistant to rifampicin, in line with some therapeutic guidelines.
Maltese: Profilassi ta' infezzjonijiet invażivi ta' adulti minħabba Neisseria meningitides Ciprofloxacin jintuża fil-prattika klinika fil-profilassi ta' infezzjonijiet invażivi ta' adulti minħabba Neisseria meningitidis meta rifampicin huwa kontraindikat jew wara dokumentazzjoni mikrobijoloġika meta Neisseria meningitidis hija reżistenti għal rifampicin, b'mod konformi ma' xi linji gwidi terapewtiċi.
English: In a clinical study with healthy subjects, there was an increase in serum tizanidine concentration (Cmax increase: 7-fold, range: 4 to 21-fold; AUC increase: 10-fold, range: 6 to 24-fold) when given concomitantly with ciprofloxacin.
Maltese: Fi studju kliniku b'individwi b'saħħithom, kien hemm żjieda fil-konċentrazzjoni ta' tizanidine fis-serum (żjieda f'Cmax: 7 darbiet, firxa: 4 sa 21 darba; żjieda fl-AUC: 10 darbiet, firxa: 6 sa 24 darba) meta mogħti flimkien ma' ciprofloxacin.
English: Neisseria gonorrhoeae* Proteus mirabilis*
Maltese: Klebsiella pneumoniae* Morganella morganii* Neisseria gonorrhoeae* Proteus mirabilis*
English: A 60-minute infusion of 400 mg ciprofloxacin every 8 hours is equivalent with respect to AUC to 750 mg oral regimen given every 12 hours.
Maltese: Infużjoni fil-vini ta' 60 minuta ta' 400 mg ciprofloxacin kull 8 sigħat hija ekwivalenti għal kors orali ta' 750 mg mogħti kull 12-il siegħa rigward l-AUC.
English: These reactions are more frequent if the infusion time is 30 minutes or less.
Maltese: Dawn irreazzjonijiet huma aktar frekwenti jekk il-ħin ta' l-infużjoni huwa 30 minuta jew inqas.
English: A 500 mg oral dose given every 12 hours has been shown to produce an area under the serum concentration-time curve (AUC) equivalent to that produced by an intravenous infusion of 400 mg ciprofloxacin given over 60 minutes every 12 hours.
Maltese: Doża orali ta' 500 mg mogħtija kull 12-il siegħa intweriet li tipproduċi erja taħt il-kurva talkonċentrazzjoni fis-serum kontra l-ħin (AUC) ekwivalenti għal dik prodotta minn infużjoni ġol-vini ta' 400 mg ciprofloxacin mogħtija fuq medda ta' 60 minuta kull 12-il siegħa.
English: In the event of any signs and symptoms of hepatic disease (such as anorexia, jaundice, dark urine, pruritus, or tender abdomen), treatment should be discontinued.
Maltese: F'każ ta' xi sinjali u sintomi ta' marda tal-fwied (bħal anoressija, suffejra, awrina skura, ħakk, jew addome teneru), il-kura għandha titwaqqaf.
English: Aerobic Gram-negative micro-organisms Acinetobacter baumannii+ Burkholderia cepacia+*
Maltese: Mikro-organiżmi aerobiċi Gram-negative Acinetobacter baumannii+ Burkholderia cepacia+* Campylobacter spp.+* Citrobacter freundii* Enterobacter aerogenes Enterobacter cloacae* Escherichia coli*
English: Protein binding of ciprofloxacin is low (20-30%).
Maltese: It-twaħħil mal-proteini ta' ciprofloxacin huwa baxx (20-30%).
English: 500 mg oral suspension (in single dose sachets)
Maltese: 500 mg suspensjoni orali (fi qratas b'doża waħda)
English: • Severe, sudden allergic reaction (an anaphylactic reaction/shock, angio-oedema).
Maltese: Reazzjoni allerġika, severa f'daqqa (reazzjoni/xokk anafilattiku, anġjo-edima).
English: 400 mg twice daily to 400 mg three times a day max. of 3 months
Maltese: 400 mg darbtejn kuljum sa 400 mg tlitt darbiet kuljum massimu ta' 3 xhur
English: CIPROXIN 250 mg/5 ml oral suspension oral use
Maltese: CIPROXIN 250 mg/5 ml suspensjoni orali użu orali
English: In this leaflet:
Maltese: Trattament ta' Shigellożi:
English: The 400 mg intravenous dose administered over 60 minutes every 12 hours resulted in a Cmax similar to that observed with a 750 mg oral dose.
Maltese: Id-doża fil-vini ta' 400 mg mogħtija fuq medda ta' 60 minuta kull 12-il siegħa wasslet għal Cmax simili għal dik osservata b'doża orali ta' 750 mg.
English: Oral ant-icoagulants
Maltese: Anoressija Ipergliċemija
English: Confusion and disorientation Anxiety reaction Abnormal dreams Depression Hallucinations
Maltese: Konfużjoni u diżorjentament Reazzjoni ta' ansjetà Ħolm mhux normali Depressjoni Alluċinazzjonijiet
English: On concurrent administration of Ciprofloxacin and caffeine or pentoxifylline (oxpentifylline), raised serum concentrations of these xanthine derivatives were reported.
Maltese: Wara għoti fl-istess waqt ta' ciprofloxacin u kafeina jew pentoxifylline (oxpentifylline), kienu rrapportati konċentrazzjonijiet fis-serum ta' dawn id-derivati ta' xanthine miżjuda.
English: Skin and Subcutaneous Tissue
Maltese: Connective Tissue
English: Vomiting Gastrointestin al and abdominal pains
Maltese: Rimettar Weġgħat gastrointestinali u addominali Dispepsja Gass
English: Only a small quantity of ciprofloxacin (<10%) is eliminated by haemodialysis or peritoneal dialysis.
Maltese: Kwantità żgħira biss ta' ciprofloxacin (<10%) hija eliminata permezz ta' emodijalisi jew dijalisi talperitonew.
English: CIPROXIN 250 mg oral suspension oral use
Maltese: CIPROXIN 250 mg suspensjoni orali użu orali
English: CIPROXIN 500 mg/5 ml oral suspension oral use
Maltese: CIPROXIN 500 mg/5 ml suspensjoni orali użu orali
English: CIPROXIN 500 mg oral suspension oral use
Maltese: CIPROXIN 500 mg suspensjoni orali użu orali
English: 100 mg/ml oral suspension oral use
Maltese: 100 mg/ml suspensjoni orali użu orali
English: Berkshire RG14 1JA United Kingdom Trading as: Bayer plc, Bayer Schering Pharma
Maltese: Bayer plc, Bayer Schering Pharma
English: NaCl Load
Maltese: Kwantità ta' NaCl
English: 2 to 4 weeks (acute) to 4 to6 weeks (chronic)
Maltese: 2 sa 4 ġimgħat (akuta) sa 4 sa6 ġimgħat (kronika)
English: The following sections of the SPC were also subject to extensive harmonisation during this referral procedure, namely sections 4.4 Special warnings and precautions, 4.5 Interactions, 4.6 Pregnancy and lactation, 4.8 Undesirable effects, 4.9 Overdose, 5.1 Pharmacodynamic properties, and 5.2 Pharmacokinetic properties.
Maltese: Prodotti mediċinali oħra li ma jaqblux ma' dan il-prodott u affarjiet oħra li jistgħu jibdlu leffett farmaċewtiku tal-prodott, 4.6 Tqala u Treddigħ, 4.8 Effetti mhux mixtieqa, 4.9 Doża eċċessiva, 5.1 Tagħrif farmakodinamiku, u 5.2 Tagħrif farmakokinetiku.
English: ADRs derived from clinical studies and post-marketing surveillance with Ciprofloxacin Bayer (oral, intravenous and sequential therapy) sorted by categories of frequency are listed below.
Maltese: ADRs derivati mill-istudji kliniċi u minn sorveljanza ta' wara t-tqegħid fis-suq ta' Ciprofloxacin Bayer (terapija orali, ġol-vini u sekwenzjali) rranġati skond il-kategoriji ta' frekwenza huma mniżżla isfel.
English: The CHMP asked the applicant/MAH to provide a substantiated discussion on the use of ciprofloxacin in prophylaxis of invasive infections of adults, to harmonize the therapeutic management of patients.
Maltese: Is-CHMP talab lill-applikant/MAH biex jagħti diskussjoni ssostanzjata dwar l-użu ta' ciprofloxacin fi profilassi ta' infezzjonijiet invażivi tal-adulti, biex is-sistema terapewtika tal-pazjenti tkun armonizzata.
English: 500 mg twice daily 60 days from the confirmation of Bacillus anthracis exposure
Maltese: 500 mg darbtejn kuljum 60 ġurnata mill-konferma ta' esponiment għal Bacillus anthracis
English: Netherlands: Ciproxin Poland:
Maltese: Ciproxine Malta:
English: Muscular weakness Tendinitis Tendon rupture (predominan tly Achilles tendon) (see section 4.4) Exacerbation of symptoms of myasthenia gravis (see section 4.4)
Maltese: Indebboliment muskolari Tendinite Tiċrit tattendon (l-aktar Achilles tendon) (ara sezzjoni 4.4) Rkadar tassintomi ta' myasthenia gravis (ara sezzjoni 4.4)
English: The recommended dosage can be higher (750 mg bid) depending on the severity and the microorganism.
Maltese: Id-dożaġġ irrakkomandat jista' jkun ogħla (750 mg bid) li jiddependi fuq is-severità u l-mikroorganiżmu.
English: Severe infections and mixed infections with Gram-positive and anaerobic pathogens Ciprofloxacin monotherapy is not suited for treatment of severe infections and infections that might be due to Gram-positive or anaerobic pathogens.
Maltese: Ciprofloxacin bħala monoterapija mhux adattat għall-kura ta' infezzjonijiet severi u ta' infezzjonijiet imħalta li jistgħu jkunu kkawżati minn patoġeni Gram-positive jew anaerobiċi.
English: 250 mg oral suspension (in single dose sachets)
Maltese: 250 mg suspensjoni orali (fi qratas b'doża waħda)
English: Ciprofloxacin Bayer may make you feel less alert.
Maltese: Ciprofloxacin Bayer jista' jġalgħek tħossok inqas alert.
English: However, 500 mg bid PO was considered inadequate for the treatment of malignant external otitis, and a dose of 750 mg bid PO was recommended for oral administration.
Maltese: Madankollu, 500 mg bid PO kienu ikkunsidrati mhux adegwati għat-trattament ta' otite esterna malinna, u doża ta' 750 mg bid PO kienet irrakkomandata għal għoti orali.
English: If you suffer from depression or psychosis, your symptoms may become worse under treatment with Ciprofloxacin Bayer.
Maltese: Jekk issofri minn depressjoni jew psikosi, is-sintomi tiegħek jistgħu jaggravaw waqt kura b'Ciprofloxacin Bayer.
English: Petechiae Erythema multiforme Erythema nodosum StevensJohnson syndrome (potentially lifethreatening) Toxic epidermal necrolysis (potentially lifethreatening)
Maltese: Eritima multiforme Eritima nodosum Sindrome StevensJohnson (b'potenzjal ta' periklu għall-ħajja) Nekrolisi epidermika tossika (b'potenzjal ta' periklu għall-ħajja)
English: SPC Section 4.2 Posology and method of administration
Maltese: SPC Sezzjoni 4.2 Pożoloġija u metodu ta' kif għandu jingħata
English: Like a number of other quinolones, ciprofloxacin is phototoxic in animals at clinically relevant exposure levels.
Maltese: Bħal numru ta' quinolones oħra, ciprofloxacin huwa fototossiku fil-bhejjem f'livelli ta' esponiment klinikament rilevanti.
English: Photosensitivity reactions (see section 4.4)
Maltese: Reazzjonijet ta' fotosensittività (ara sezzjoni 4.4)
English: Haemolytic reactions have been reported with ciprofloxacin in patients with glucose-6-phosphate dehydrogenase deficiency.
Maltese: Defiċjenza ta' glucose-6-phosphate dehydrogenase F'pazjenti b'defiċjenza ta' glucose-6-phosphate dehydrogenase, kienu rrapportati reazzjonijiet emolitiċi b'ciprofloxacin.
English: ½ measuring spoonful (approx 2.5 mL suspension) provides approx. 250 mg ciprofloxacin.
Maltese: ½ mgħarfa tal-kejl waħda (madwar 2.5 mL ta' suspensjoni) tipprovdi madwar 250 mg ta' ciprofloxacin
English: System Organ
Maltese: Reżistenti
English: • Urinary tract infections
Maltese: • infezzjonijiet fl-apparat urinarju
English: Do not add any water to the solvent.
Maltese: Ħawwad il-qartas waqt li tagħfas il-ġnubijiet bil-mod.
English: How to store Ciprofloxacin Bayer 6.
Maltese: Kif taħżen Ciprofloxacin Bayer 6.
English: The Ciprofloxacin Bayer 50 mg/mL oral suspension is indicated for the treatment of the following infections (see sections 4.4 and 5.1).
Maltese: Ciprofloxacin Bayer 50 mg/mL suspensjoni orali huwa ndikat għall-kura ta' l-infezzjonijiet li ġejjin (ara sezzjonijiet 4.4 u 5.1).
English: This effect was comparable to that of other gyrase inhibitors.
Maltese: Tista' wkoll tiżviluppa reżistenza għall-antibijotiku.
English: The simultaneous administration of ciprofloxacin (oral) and multivalent cation-containing drugs and mineral supplements (e.g. calcium, magnesium, aluminium, iron), polymeric phosphate binders (e.g. sevelamer), sucralfate or antacids, and highly buffered drugs (e.g. didanosine tablets) containing magnesium, aluminium, or calcium reduces the absorption of ciprofloxacin.
Maltese: L-għoti ta' ciprofloxacin (orali) flimkien ma' mediċini multivalenti li fihom il-cations u supplimenti ta' minerali (e.ż. kalċju, manjesju, aluminju, ħadid), sustanzi polimeriċi li jeħlu mal-fosfat (e.ż. sevelamer), sucralfate jew antaċidi, u mediċini buffered ħafna (e.ż. pilloli didanosine) li fihom manjesju, aluminju, jew kalċju jnaqqas l-assorbiment ta' ciprofloxacin.
English: - broncho-pulmonary infections in cystic fibrosis or in bronchiectasis
Maltese: - infezzjonijiet bronko-pulmonari f'fibrożi ċistika
English: Uncommon side effects (between 1 and 10 in every 1,000 people are likely to get these):
Maltese: Effetti sekondarji mhux komuni (x'aktarx li jaffettwaw minn persuna waħda sa 10 minn kull 1,000):
English: Dyspnoea (including asthmatic condition)
Maltese: Qtugħ ta' nifs (inkluż kondizzjoni ażmatika)
English: As Ciprofloxacin Bayer 100 mg/mL suspension contains 1.3 g sucrose per 5-mL measuring spoonful, this has to be taken into consideration in terms of daily intake.
Maltese: Peress li ciprofloxacin 100 mg/mL suspensjoni orali fih 1.3 g sucrose f'kull mgħarfa tal-kelj ta' 5 mL, dan għandu jiġi kkunsidrat f'termini ta' teħid ta' kuljum.
English: • Lower respiratory tract infections due to Gram-negative bacteria:
Maltese: • Infezzjonijiet fil-parti t'isfel tal-passaġġi respiratorji minħabba batterji Gram negattivi:
English: Musculoskelet al, Connective Tissue and Bone Disorders
Maltese: Muskoluskeltrali u talConnective Tissue
English: Regarding the modified release tablet SPC, no proposal for a harmonised SPC was provided.
Maltese: Ta' Rilaxx Immodifikat Rigward l-SPC tal-pillola ta' rilaxx immodifikat, ma ngħatat l-ebda proposta għal SPC armonizzat.
English: Czech Republic Bayer HealthCare AG D-51368 Leverkusen
Maltese: Ir-Repubblika Ċeka Bayer HealthCare AG D-51368 Leverkusen
English: Ciprofloxacin Bayer solution for infusion contains 10 g glucose in 200 mL solution for infusion.
Maltese: Soluzzjoni għall-infużjoni ta' ciprofloxacin fiha 10 g glucose f'200 mL ta' soluzzjoni għall-infużjoni.
English: • respiratory tract infections
Maltese: • infezzjonijiet fl-apparat respiratorju
English: Crystalluria related to the use of ciprofloxacin has been reported (see section 4.8).
Maltese: Kienet irrapportata kristallurja relata ma' l-użu ta' ciprofloxacin (ara sezzjoni 4.8).
English: In 10 children with severe sepsis Cmax was 6.1 mg/L (range 4.6-8.3 mg/L) after a 1-hour intravenous infusion of 10 mg/kg in children aged less than 1 year compared to 7.2 mg/L (range 4.7-11.8 mg/L) for children between 1 and 5 years of age.
Maltese: F'għaxart itfal b'sepsis severa, Cmax kienet 6.1 mg/L (firxa 4.6-8.3 mg/L) wara infużjoni ta' 10 mg/kg ġol-vini ta' siegħa fi tfal b'età ta' inqas minn sena meta mqabbel ma' 7.2 mg/L (firxa 4.7-11.
English: Creatinine Clearance [mL/min/ 1.73 m²]
Maltese: Tneħħija tal-krejatinina [mL/min/ 1.73 m²]
English: Posology for severe respiratory tract infections, severe bone and joint infections In severe respiratory tract infections as well as in severe bone and joint infections, higher doses than that currently recommended (such as 750 mg x 3/day or 1000 mg x 2/day) for oral route are currently used in clinical practice given the known decreased susceptibility of the main pathogens involved (including Pseudomonas aeruginosa, Acinetobacter, Staphylococcus aureus) and the severity of the disease (as well as the difficulties in reaching optimal concentration at the bone level).
Maltese: Pożoloġija għall-infezzjonijiet tal-passaġġi respiratorji, infezzjonijiet tal-għadam u tal-ġogi F'infezzjonijiet severi tal-passaġġi respiratorji kif ukoll f'infezzjonijiet severi tal-għadam u tal-ġogi, fil-preżent, fil-prattika klinika, qegħdin jintużaw dożi ogħla minn dawk rakkomandati (bħalma huma 750 mg x 3/kuljum jew 1000 mg x 2/kuljum) għar-rotta orali minħabba s-suxxettibbilità mnaqqsa magħrufa tal-patoġeni involuti (inklużi Pseudomonas aeruginosa, Acinetobacter, Staphylococcus aureus) u s-severità tal-marda (kif ukoll id-diffikultajiet biex tintlaħaq konċentrazzjoni ottima fil-livell tal-għadam).
English: However, for infections such as malignant external otitis (MEO), the scenario is different.
Maltese: Madankollu, għall-infezzjonijiet bħal otite esterna malinna (MEO), ix-xenarju huwa wieħed differenti.
English: CIPROBAY URO 100 mg film-coated tablets oral use
Maltese: CIPROBAY URO 100 mg pilloli miksija b'rita użu orali
English: Visual colour distortions
Maltese: Disturbi fil-kuluri visivi
English: • Acute exacerbations of chronic sinusitis, especially if these are caused by Gram-negative bacteria
Maltese: • Taħrixiet akuti ta' sinożite kronika, speċjalment dawk ikkaġunati minn batterji Gram-negattivi
English: Posology for the treatment of infections due to Vibrio cholerae The CHMP asked the Applicant/MAH to justify the suggested dosage regimen for the treatment of infections caused by Vibrio cholerae (oral and iv formulations).
Maltese: Pożoloġija għat-trattament ta' infezzjonijet dovuti għal Vibrio cholerae Is-CHMP talab lill-Applikant/MAH biex jiġġustifika r-reġimen tad-dożaġġ issuġġerit għal trattament ta' infezzjonijiet ikkaġunati minn Vibrio cholerae (formulazzjonijiet orali u iv).
English: 500 mg/5 ml oral suspension oral use use
Maltese: 500 mg/5 ml suspensjoni orali użu orali
English: Oral Dose [mg] See Usual Dosage.
Maltese: Dosa Orali [mg] Ara Doża tas-Soltu.
English: 50 mg/ml oral suspension oral use
Maltese: 50 mg/ml suspensjoni orali użu orali
English: • Broncho-pulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa
Maltese: • Infezzjonijiet bronko-pulmonari f'fibrożi ċistika kkawżata minn Pseudomonas aeruginosa
English: Rare side effects (between 1 and 10 in every 10,000 people are likely to get these):
Maltese: Effetti sekondarji rari (x'aktarx li jaffettwaw minn persuna waħda sa 10 minn kull 10,000):
English: A 60-minute intravenous infusion of 400 mg ciprofloxacin every 12 hours was bioequivalent to a 500 mg oral dose every 12 hours with regard to AUC.
Maltese: Infużjoni fil-vini ta' 60 minuta ta' 400 mg ciprofloxacin kull 12-il siegħa kienet bijoekwivalenti għal doża orali ta' 500 mg kull 12-il siegħa rigward l-AUC.
English: 400 mg twice daily 60 days from the confirmation of Bacillus anthracis exposure
Maltese: 60 ġurnata millkonferma ta' esponiment għal Bacillus anthracis
English: Glucose-6-phosphate dehydrogenase deficiency
Maltese: Żjieda flalkaline phosphatase fid-demm
English: Unless compatibility with other infusion solutions/drugs has been confirmed, the infusion solution must always be administered separately.
Maltese: Sakemm ma tkunx ikkonfermata kompatibilità ma' soluzzjonijiet għall-infużjoni/mediċini oħra, issoluzzjoni għall-infużjoni għandha dejjem tingħata separatament.
English: CIPROBAY 750 mg film-coated tablets oral use
Maltese: CIPROBAY 750 mg pilloli miksija b'rita użu orali
English: 1 measuring spoonful (approx 5.0 mL suspension) provides approx. 500 mg ciprofloxacin.
Maltese: Mgħarfa tal-kejl waħda (madwar 5.0 mL ta' suspensjoni) tipprovdi madwar 500 mg ta' ciprofloxacin.
English: Czech Republic: Ciprobay Uro Germany:
Maltese: Ir-Repubblika Ċeka: Ciprobay Uro Il-Ġermanja:
English: • Inhalation anthrax (post-exposure prophylaxis and curative treatment) Children and adolescents
Maltese: • Antraċe meħud man-nifs (profilassi wara esponiment u kura ta' fejqan) Tfal u adoloxxenti
English: • Lower respiratory tract infections due to Gram-negative bacteria exacerbations of chronic obstructive pulmonary disease broncho-pulmonary infections in cystic fibrosis or in bronchiectasis pneumonia
Maltese: Infezzjonijiet ta' l-apparat respiratorju ta' isfel ikkawżati minn batterja Gram-negative - irkadar tal-marda pulmonari ostruttiva kronika - infezzjonijiet bronko-pulmonari f'fibrożi ċistika jew f'bronkjektasi - pnewmonja
English: 10 g/100 ml oral suspension oral use
Maltese: 10 g/100 ml suspensjoni orali użu orali
English: Streptococcal Infections (including Streptococcus pneumoniae) Ciprofloxacin is not recommended for the treatment of streptococcal infections due to inadequate efficacy.
Maltese: Infezzjonijiet ikkawżati minn Streptococci (inkluż Streptococcus pneumoniae) Ciprofloxacin mhux irrakkomandat għall-kura ta' infezzjonijiet ikkawżati minn streptococci ta' minħabba effikaċja mhux adegwata.
English: 5 g/100 ml oral suspension oral use
Maltese: 5 g/100 ml suspensjoni orali użu orali